Published in World J Urol on October 18, 2013
Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment | NCT03229889
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg (2004) 55.13
Flexible ureteroscopy and laser lithotripsy for multiple unilateral intrarenal stones. Eur Urol (2008) 2.97
Ureteral stenting and urinary stone management: a systematic review. J Urol (2008) 2.71
Classification of percutaneous nephrolithotomy complications using the modified clavien grading system: looking for a standard. Eur Urol (2007) 2.62
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. J Urol (2012) 2.34
Postureteroscopic lesion scale: a new management modified organ injury scale--evaluation in 435 ureteroscopic patients. J Endourol (2012) 2.15
Complications of 2735 retrograde semirigid ureteroscopy procedures: a single-center experience. J Endourol (2006) 1.91
Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ (2007) 1.71
EAU guidelines on urological trauma. Eur Urol (2005) 1.70
The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: a systematic review and meta-analysis. J Urol (2011) 1.66
Organ injury scaling. III: Chest wall, abdominal vascular, ureter, bladder, and urethra. J Trauma (1992) 1.27
Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials. J Urol (2012) 1.24
Advanced ureteroscopy: wireless and sheathless. J Endourol (2006) 1.04
Impact of stone location on success rates of endoscopic lithotripsy for nephrolithiasis. Urology (2008) 1.02
Use of Clavien-Dindo classification in reporting and grading complications after urological surgical procedures: analysis of 2010 to 2012. J Urol (2013) 1.00
Categorization of intraoperative ureteroscopy complications using modified Satava classification system. World J Urol (2013) 0.94
The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis. Urology (2008) 0.88
Retrograde intrarenal surgery in treatment of nephrolithiasis: is a 100% stone-free rate achievable? J Endourol (2012) 0.83
A plea for centralized care for ureteroscopy: results from a comparative study under different conditions within the same center. J Endourol (2011) 0.77
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
2007 guideline for the management of ureteral calculi. J Urol (2007) 4.44
2007 Guideline for the management of ureteral calculi. Eur Urol (2007) 3.98
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18
Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol (2008) 2.97
The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res (2012) 2.94
Novel artificial neural network for early detection of prostate cancer. J Clin Oncol (2002) 2.88
The clinical research office of the endourological society ureteroscopy global study: indications, complications, and outcomes in 11,885 patients. J Endourol (2013) 2.82
ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res (2010) 2.79
ConsensusPathDB--a database for integrating human functional interaction networks. Nucleic Acids Res (2008) 2.77
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol (2006) 2.77
A gene expression map of human chromosome 21 orthologues in the mouse. Nature (2002) 2.76
Impact of preoperative ureteral stenting on stone-free rates of ureteroscopy for nephroureterolithiasis: a matched-paired analysis of 286 patients. Urology (2012) 2.70
Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. Int J Urol (2014) 2.68
Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg (2007) 2.68
Computational analysis of genome-wide DNA methylation during the differentiation of human embryonic stem cells along the endodermal lineage. Genome Res (2010) 2.61
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Laparoendoscopic single-site surgery in urology: worldwide multi-institutional analysis of 1076 cases. Eur Urol (2011) 2.46
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol (2009) 2.44
Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol (2007) 2.39
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Catalytic enantioselective reactions driven by photoinduced electron transfer. Nature (2005) 2.37
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res (2004) 2.29
Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol (2006) 2.29
Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol (2012) 2.28
Efficacy of medical expulsive treatment with doxazosin in pediatric patients. Urology (2013) 2.26
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Topographical anatomy of periprostatic and capsular nerves: quantification and computerised planimetry. Eur Urol (2008) 2.22
A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol (2010) 2.21
Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells (2006) 2.18
120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up. BJU Int (2011) 2.17
Postureteroscopic lesion scale: a new management modified organ injury scale--evaluation in 435 ureteroscopic patients. J Endourol (2012) 2.15
Nerve quantification and computerized planimetry to evaluate periprostatic nerve distribution-does size matter? Urology (2009) 2.14
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Percutaneous nephrolithotomy made easier: a practical guide, tips and tricks. BJU Int (2007) 2.09
Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis. Eur Urol (2013) 2.09
Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol (2010) 2.07
A prospective evaluation of pain associated with stone passage, stents, and stent removal using a visual analog scale. Urology (2013) 2.05
Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol (2012) 2.04
Percutaneous management of calculi within horseshoe kidneys. J Urol (2003) 2.04
Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol (2007) 2.04
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res (2004) 2.03
Second cancers as competing causes of death after radical prostatectomy. J Urol (2009) 2.02
Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Arch Ital Urol Androl (2015) 1.95
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
Percutaneous nephrolithotomy with ultrasonography-guided renal access: experience from over 300 cases. BJU Int (2005) 1.91
Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol (2006) 1.90
DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol (2004) 1.89
Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol (2009) 1.87
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. Eur Urol (2007) 1.82
Holmium:YAG laser lithotripsy for upper urinary tract calculi in 598 patients. J Urol (2002) 1.82
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol (2004) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
980-nm Diode laser: a novel laser technology for vaporization of the prostate. Eur Urol (2007) 1.79
Shock wave technology and application: an update. Eur Urol (2011) 1.77
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol (2011) 1.71
Primary differentiation in the human blastocyst: comparative molecular portraits of inner cell mass and trophectoderm cells. Stem Cells (2005) 1.68
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol (2004) 1.65
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
New evidence for genome-wide duplications at the origin of vertebrates using an amphioxus gene set and completed animal genomes. Genome Res (2003) 1.65
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood (2006) 1.64
Flexible ureterorenoscopy with holmium laser in horseshoe kidneys. Urology (2010) 1.63
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Behavior, intention or chance? A longitudinal study of HIV seroadaptive behaviors, abstinence and condom use. AIDS Behav (2012) 1.62
Kidney fusion anomalies revisited: clinical and radiological analysis of 209 cases of crossed fused ectopia and horseshoe kidney. BJU Int (2008) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol (2009) 1.60
Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest (2003) 1.60
The CROES percutaneous nephrolithotomy global study: the influence of body mass index on outcome. J Urol (2012) 1.59
Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2012) 1.58
Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol (2011) 1.58
Ureteroscopy and holmium:YAG laser lithotripsy: an emerging definitive management strategy for symptomatic ureteral calculi in pregnancy. Urology (2002) 1.57
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
The use of a thermoexpandable metal alloy stent in the minimally invasive management of retroperitoneal fibrosis: a single center experience from the United kingdom. J Endourol (2013) 1.57
Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate (2002) 1.56
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. Eur Urol (2011) 1.55
Comparison of intrarenal pelvic pressure during micro-percutaneous nephrolithotomy and conventional percutaneous nephrolithotomy. Urolithiasis (2014) 1.55
Intrafascial nerve-sparing endoscopic extraperitoneal radical prostatectomy. Eur Urol (2007) 1.53
Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up. J Endourol (2011) 1.51